Floatz logo

FILGRASTIM

T-cell Leukemia

Xinqiao Hospital of Chongqingprotein_peptideEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the T-cell Leukemia cohort.

Asset / SponsorPhaseRating
A-DMDT390-BISFV(UCHT1)
Virogen Biotechnology Inc.
Phase 2CCC
MOGAMULIZUMAB
Memorial Sloan Kettering Cancer Center
Phase 2CCC
cd19-ucart
Beijing Boren Hospital
Phase 1CCC
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Children's Oncology Group
Phase 1CC
PREDNISONE TABLETS
Children's Oncology Group
Phase 1CC

View all 13 →

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
79 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →